NASDAQ · LFCRHealthcarePharmaceuticals

Lifecore Biomedical news

$6.59+1.07%
Close Sep 29, 2026 · split-adjusted
Articles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0

About Lifecore Biomedical

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Lifecore Biomedical, Inc. Securities - LFCR
GlobeNewswire Inc.Apr 6, 8:00 AM ET▼ Negative

The company is the defendant in a class action lawsuit involving alleged securities fraud during the period October 2020 to March 2024. The settlement of $3.75 million indicates legal liability and potential misconduct by company leadership, which is negative for shareholders and the company's reputation.

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
GlobeNewswire Inc.Mar 23, 7:00 AM ET▲ Positive

The company secured its third commercial site transfer in five months, demonstrating strong execution of its strategic plan. The agreement is expected to generate revenue within 24 months and contribute to the company's 12% 2029 revenue CAGR target. Management expressed confidence in leveraging market momentum and building a stronger growth portfolio. This represents successful business development and validates the company's shift toward lower-risk, late-stage programs.

Also mentions LFCR

Articles that tag LFCR but are mainly about other companies.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology